Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population.

Johansson, P., Mattsson, N., Hansson, O., Wallin, A., Johansson, J.O., Andreasson, U., Zetterberg, H., Blennow, K., Svensson, J.
Journal   J Alzheimers Dis.
Species  
Analytes Measured   Abeta 38 , Abeta 40 , Abeta 42 , APP
Matrix Tested   Cerebrospinal fluid (CSF)
Year   2011
Volume  
Page Numbers  
Application   Alzheimers
Abstract
The cerebrospinal fluid (CSF) biomarkers amyloid-β (Aβ)(1-42), T-tau, and P-tau have good diagnostic accuracy for clinically diagnosed Alzheimer’s disease (AD). However, in multi-center studies, the predictive values of the CSF biomarkers have been lower, possibly due to differences in procedures for lumbar puncture and CSF handling and storage, and to differences in patient populations, clinical evaluations, and diagnostic procedures. Here we investigate the diagnostic accuracy of CSF biomarkers in a well defined homogeneous mono-center population. We also evaluate an extended panel of amyloid related biomarkers. Sixty consecutive patients admitted for cognitive impairment to a memory clinic were recruited. The participants included patients with AD or mild cognitive impairment (MCI) diagnosed with AD upon follow-up (n = 32), patients with stable MCI (n = 13), patients with other dementias diagnosed at primary evaluation or upon follow-up (n = 15), and healthy controls(n = 20). CSF was analyzed for Aβ(1-42), T-tau, and P-tau, and PA(X-38), Aβ(X-40), Aβ(X-42), sAβPPα, and sAβPPβ. In multivariate analysis, thecore biomarkers Aβ(1-42), T-tau, and P-tau demonstrated a high ability to diagnose AD versus the combined groups of controls and stable MCI, with an area under the receiver operating characteristic curve (AUROC) of 0.97 (95% CI 0.93–1.00, p < 0.0001). The additional biomarkers only marginally increased AUROC to 0.98 (95% CI 0.95–1.00, p < 0.0001), this increase mainly mediated by Aβ(X-42). In conclusion, CSF biomarkers Aβ(1-42), T-tau, and P-tau have very high diagnostic accuracy in a well defined cohort of untreated patients, demonstrating the excellent potency of CSF biomarkers to identify pathological processes in AD when astringent analytical protocol is used.

View Publications

Related Products

R-PLEX Human Aβ42 (6E10) Antibody Set
Aβ42 (6E10) | Human
Singleplex
NEW
R-PLEX Human Aβ40 (6E10) Antibody Set
Aβ40 (6E10) | Human
Singleplex
NEW
Human (6E10) Aβ38 Ultra-Sensitive Kit
Aβ38 | Human
Singleplex
Human (6E10) Aβ40 Ultra-Sensitive Kit
Aβ40 | Human
Singleplex
Human (6E10) Aβ42 Ultra-Sensitive Kit
Aβ42 | Human
Singleplex
V-PLEX Human Aβ42 Kit
Aβ42 | Human
Singleplex
V-PLEX Aβ Peptide Panel 1 (4G8) Kit
Aβ38, Aβ40, Aβ42 | Human, Mouse, Rat
Multiplex
V-PLEX Aβ Peptide Panel 1 (6E10) Kit
Aβ38, Aβ40, Aβ42 | Human
Multiplex
V-PLEX Aβ40 Peptide (4G8) Kit
Aβ40 | Human, Mouse, Rat
Singleplex
V-PLEX Aβ40 Peptide (6E10) Kit
Aβ40 | Human
Singleplex
V-PLEX Aβ42 Peptide (4G8) Kit
Aβ42 | Human, Mouse, Rat
Singleplex
V-PLEX Plus Aβ Peptide Panel 1 (4G8) Kit
Aβ38, Aβ40, Aβ42 | Human, Mouse, Rat
Multiplex
V-PLEX Plus Aβ Peptide Panel 1 (6E10) Kit
Aβ38, Aβ40, Aβ42 | Human
Multiplex
V-PLEX Plus Aβ40 Peptide (4G8) Kit
Aβ40 | Human, Mouse, Rat
Singleplex
V-PLEX Plus Aβ40 Peptide (6E10) Kit
Aβ40 | Human
Singleplex
V-PLEX Plus Aβ42 Peptide (4G8) Kit
Aβ42 | Human, Mouse, Rat
Singleplex
V-PLEX Plus Human Aβ42 Kit
Aβ42 | Human
Singleplex
Neurodegeneration Control Pack 1
Aβ38, Aβ40, Aβ42, Tau (total) | Human, Mouse, Rat
sAPPα Kit
APP | Human
Multiplex
sAPPβ Kit
APP | Human
Singleplex
sw sAPPβ Kit
APP | Human
Singleplex
sAPPα/sAPPβ Kit
APP | Human
Multiplex
V-PLEX Aβ38 Peptide (4G8) Kit
Aβ38 | Human, Mouse, Rat
Singleplex
V-PLEX Aβ38 Peptide (6E10) Kit
Aβ38 | Human
Singleplex
V-PLEX Plus Aβ38 Peptide (4G8) Kit
Aβ38 | Human, Mouse, Rat
Singleplex
V-PLEX Plus Aβ38 Peptide (6E10) Kit
Aβ38 | Human
Singleplex
Browse Our Products

By Analytes
By Applications
Search
Customer Service/Orders


Scientific/Technical Support


Instrument Support


Company Headquarters